Literature DB >> 24929121

Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis.

Esther Vorovich1, Benjamin French2, Bonnie Ky2, Lee Goldberg1, James C Fang3, Nancy K Sweitzer4, Thomas P Cappola5.   

Abstract

BACKGROUND: Identification of heart failure (HF) patients at risk for hospitalization may improve care and reduce costs. We evaluated 9 biomarkers as predictors of cardiac hospitalization in chronic HF. METHODS AND
RESULTS: In a multicenter cohort of 1,512 chronic HF outpatients, we assessed the association between 9 biomarkers and cardiac hospitalization with the use of a recurrent events approach. Over a median follow-up of 4 years, 843 participants experienced ≥ 1 hospitalizations (total 2,178 hospitalizations). B-type natriuretic peptide (BNP) and troponin I (TnI) exhibited the strongest associations with risk of hospitalization (hazard ratio [HR] 3.8 [95% confidence interval (CI) 2.9-4.9] and HR 3.3 [95% CI 2.8-3.9]; 3rd vs 1st tertiles). Soluble Fms-like tyrosine kinase receptor 1 (sFlt-1) exhibited the next strongest association (HR 2.8 [95% CI 2.4-3.4]), followed by soluble Toll-like receptor 2 (HR 2.3 [95% CI 2.0-2.8]) and creatinine (HR 1.9 [95% CI 1.6-2.4]). Within ischemic/nonischemic subgroups, BNP and TnI remained most strongly associated. Except for creatinine, HRs for all biomarkers studied were smaller within the ischemic subgroup, suggesting greater importance of cardiorenal interactions in decompensation of ischemic HF.
CONCLUSION: Although BNP and TnI exhibited the strongest associations with hospitalization, etiology-dependent associations for the remaining biomarkers suggest etiology-specific mechanisms for HF exacerbation. sFlt-1 exhibited a strong association with cardiac hospitalization, highlighting its potential role as a biomarker of HF morbidity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BNP; recurrent hospitalization; sFlt-1; troponin

Mesh:

Substances:

Year:  2014        PMID: 24929121      PMCID: PMC4142349          DOI: 10.1016/j.cardfail.2014.05.013

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  32 in total

1.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

2.  Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure.

Authors:  Audrey H Wu; Jalal K Ghali; Gerald W Neuberg; Christopher M O'Connor; Peter E Carson; Wayne C Levy
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

3.  Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure.

Authors:  W H Wilson Tang; Kevin Shrestha; Richard W Troughton; Allen G Borowski; Allan L Klein
Journal:  Congest Heart Fail       Date:  2011-03-31

4.  High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2010-12-22       Impact factor: 8.790

5.  Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006.

Authors:  Paul A Heidenreich; Anju Sahay; John R Kapoor; Michael X Pham; Barry Massie
Journal:  J Am Coll Cardiol       Date:  2010-07-27       Impact factor: 24.094

6.  Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction.

Authors:  John T Parissis; Ignatios Ikonomidis; Pinelopi Rafouli-Stergiou; Alexandre Mebazaa; Juan Delgado; Dimitrios Farmakis; Fabio Vilas-Boas; Ioannis Paraskevaidis; Maria Anastasiou-Nana; Ferenc Follath
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

7.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

8.  Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.

Authors:  Wayne L Miller; Karen A Hartman; Mary F Burritt; Diane E Grill; Richard J Rodeheffer; John C Burnett; Allan S Jaffe
Journal:  Circulation       Date:  2007-06-25       Impact factor: 29.690

9.  Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure.

Authors:  Wayne L Miller; Karen A Hartman; Mary F Burritt; Diane E Grill; Allan S Jaffe
Journal:  J Am Coll Cardiol       Date:  2009-10-27       Impact factor: 24.094

10.  Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

Authors:  Roberto Latini; Serge Masson; Inder S Anand; Emil Missov; Marjorie Carlson; Tarcisio Vago; Laura Angelici; Simona Barlera; Giovanni Parrinello; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn
Journal:  Circulation       Date:  2007-08-13       Impact factor: 29.690

View more
  10 in total

Review 1.  Diastolic dysfunction.

Authors:  Euy-Myoung Jeong; Samuel C Dudley
Journal:  Circ J       Date:  2015-02-05       Impact factor: 2.993

2.  Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study.

Authors:  Cecilia Berardi; David A Bluemke; Brian A Houston; Todd M Kolb; João A Lima; Theo Pezel; Ryan J Tedford; Samuel G Rayner; Richard K Cheng; Peter J Leary
Journal:  J Heart Lung Transplant       Date:  2022-01-10       Impact factor: 13.569

3.  Assessment of Diastolic Function Using Ultrasound Elastography.

Authors:  Maryam Vejdani-Jahromi; Jenna Freedman; Young-Joong Kim; Gregg E Trahey; Patrick D Wolf
Journal:  Ultrasound Med Biol       Date:  2018-01-10       Impact factor: 2.998

4.  Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia.

Authors:  M C Honigberg; D E Cantonwine; A M Thomas; K-H Lim; S I Parry; T F McElrath
Journal:  J Perinatol       Date:  2015-11-19       Impact factor: 2.521

5.  Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.

Authors:  Milton Packer; James L Januzzi; Joao Pedro Ferreira; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Martina Brueckmann; Waheed Jamal; Daniel Cotton; Tomoko Iwata; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2021-06-21       Impact factor: 17.349

Review 6.  Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.

Authors:  Alexander E Berezin
Journal:  J Circ Biomark       Date:  2016-03-16

7.  Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome.

Authors:  Marijke van der Meulen; Susanna den Boer; Gideon J du Marchie Sarvaas; Nico Blom; Arend D J Ten Harkel; Hans M P J Breur; Lukas A J Rammeloo; Ronald Tanke; Ad J J C Bogers; Willem A Helbing; Eric Boersma; Michiel Dalinghaus
Journal:  ESC Heart Fail       Date:  2021-02-05

Review 8.  New aspects in cardiorenal syndrome and HFpEF.

Authors:  Ana Belén Méndez; Maria Antonieta Azancot; Aleix Olivella; María José Soler
Journal:  Clin Kidney J       Date:  2022-05-06

Review 9.  Biomarkers in Cardiorenal Syndromes.

Authors:  Shihui Fu; Shaopan Zhao; Ping Ye; Leiming Luo
Journal:  Biomed Res Int       Date:  2018-03-05       Impact factor: 3.411

10.  Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.

Authors:  Nasser Davarzani; Sandra Sanders-van Wijk; Micha T Maeder; Peter Rickenbacher; Evgueni Smirnov; Joël Karel; Thomas Suter; Rudolf A de Boer; Dirk Block; Vinzent Rolny; Christian Zaugg; Matthias E Pfisterer; Ralf Peeters; Hans-Peter Brunner-La Rocca
Journal:  EPMA J       Date:  2018-05-13       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.